CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 19 enrolled / 19 target
Drug / intervention
Avatrombopag Oral Tabletdrug
Likely dose
Avatrombopag Oral Tablet 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05369208
NCT05369208Phase 3CompletedUpdate Overdue (0.4/mo)Completion was 29mo ago
CompareCT.gov

An Open-label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic Immune Thrombocytopenia

Sobi, Inc.·interventional·Posted May 11, 2022·Updated Jun 3, 2026

In Brief

A Phase 3 clinical trial evaluating Avatrombopag Oral Tablet for Immune Thrombocytopenia. Completed, enrolled 19 participants across 19 sites.

Signals

Enrollment appears stalled

Detailed Summary

Evaluate the efficacy, safety, and PK of avatrombopag given for 26 weeks in Japanese adults with chronic immune thrombocytopenia (ITP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedMay 11, 2022
Enrollment StartJun 15, 2022
Primary CompletionJan 17, 2024
Study CompletionOct 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.1 years ago

Arms & Interventions

Avatrombopagother

Avatrombopag 20 mg oral tablet

Drug: Avatrombopag Oral Tablet

Interventions

Avatrombopag Oral Tabletdrug

Avatrombopag 20 mg given once daily (initial dose). Dosage adjustments were determined by the physician to maintain a platelet count between 50 x 10\^9 to 200 x 10\^9 as defined in the protocol and in accordance with overseas labeling.